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Abstract 
Advanced nanostructured materials, such as gold 
nanoparticles, magnetic nanoparticles and 
multifunctional materials, are nowadays used in 
many state-of-the-art biomedical application. 
However, although the engineering in this field is 
very advanced, there remain some fundamental problems involving the interaction mechanisms 
between nanostructures and cells or tissues. Here we show the potential of 1H-NMR in the 
investigation of the uptake of two different kinds of nanostructures i.e. maghemite and gold 
nanoparticles, and of a chemotherapy drug (temozolomide), in glioblastoma tumor cells. The 
proposed experimental protocol provides a new way to investigate the general problem of 
cellular uptake for a variety of biocompatible nanostructures and drugs. 
 
The role of nanoscience is currently of primary importance in the development of innovative 
strategies in the fields of nanomedicine and personalized medicine. Several in vitro studies and 
pre-clinical trials have been undertaken on a great variety of nanostructures: among these, 
magnetic nanoparticles and gold nanoparticles represent the core of several advanced biomedical 
applications. On the one hand, magnetic nanoparticles of novel synthesis can improve the 
capabilities of already existing and widely used clinical diagnostic and therapeutic techniques1-3, 
like e.g. molecular imaging4-6, magnetic fluid hyperthermia7 and magnetofection8, acting as 
contrast agents, markers and carriers respectively. Moreover, the possibility of new approaches 
to synthesize a single nanostructure with more than one function9-11 gives the opportunity to 
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overcome the limitations of standard medicine. On the other hand, gold nanoparticles are used in 
several biomedical applications: due to their versatility, their physical properties and the easy 
synthesis procedure, functionalized gold nanoparticles play an important role in some advanced 
antitumor therapies, allowing an enhancement of X-ray radiation cross section (useful in 
radiotherapy and in CT diagnosis) or improving drug solubility11-13. 
Despite the great amount of scientific research produced during the last 10 years in the field of 
magnetic and metallic nanoparticles, concerning in particular engineering and design 
characteristics of nanostructures15-18, there are still some critical points regarding basic aspects of 
the interaction between exogenous nanostructures and biological systems19; indeed, the cell 
uptake of nanoparticles after their injection into the circulation is of primary importance, the 
clinical in vivo application being the final goal of these researches. Although some experimental 
techniques such as fluorescence microscopy and electron microscopy can supply qualitative 
information about the uptake mechanisms, very few techniques can provide reliable and 
quantitative  information about the mechanisms of uptake on a great variety of samples and 
biological systems22,38,39. 
In order to better understand the basic cellular uptake mechanisms at a microscopic level, we 
developed a versatile method based on broadband 1H-NMR to study the in vitro cellular response 
as a function of concentration of external agents. Indeed, 1H-NMR relaxometry experiments 
allow to measure two characteristic parameters related to the relaxation process of the hydrogen 
nuclear magnetization, i.e. the longitudinal relaxation time T1 and the transverse relaxation time 
T2. Given that these quantities depend on the interaction between the hydrogen nuclei (protons) 
and the surrounding spins and lattice, they give information about the microscopic properties of 
the sample. We tested the potential for the experimental setup using different kinds of exogenous 
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biocompatible agents, i.e. magnetic nanoparticles, gold nanoparticles and an antitumor drug 
(temozolomide), proving that this method could represent a new way to obtain quantitative 
information on a wide variety of uptake phenomena. Furthermore, in order to check the 
experimental efficacy of such a protocol on different biological systems, two different human 
glioblastoma immortalized cell lines were selected, i.e. T98G and U251. The choice of these cell 
lines was strongly supported by the great interest of the scientific community in developing more 
effective therapies (and alternatives to surgery) against such form of very aggressive brain 
cancer20,21. 
Magnetic nanoparticles (MNPs). Rhamnose-coated (magnetic core diameter = 18.2 ± 1.1 
nm) iron oxide MNPs were used. As demonstrated in Ref. 22, they resulted as good contrast 
agents for Magnetic Resonance Imaging (MRI), displaying a nuclear transverse relaxivity as 
high as 300 s-1mM-1 at 20 MHz, and good Magnetic Fluid Hyperthermia (MFH) agents, having a 
specific absorption rate (SAR) value greater than 60 W/g. Furthermore, the stability of MNPs in 
water solution was proved by DLS and TEM measurements in Ref. 22; this is allow us to 
exclude any a priori aggregation contribution to the cellular uptake37. In both techniques, an 
evaluation of the degree of cellular uptake is crucial for diagnostic and therapeutic purposes. 
After incubating the MNPs with the two different glioblastoma cell lines for 24 hours, we 
carried out experiments of intra-cellular localization by optical microscopy (Figure 1); indeed, by 
means of the Prussian Blue reaction, MNPs can be easily recognized. The results show a marked 
tendency by both cell lines to capture the nanoparticles, with a great phagocytic activity even at 
low concentrations (i.e. 2 μg/mL). Furthermore, it can be observed that MNPs are only found in 
the cytoplasm, while they are completely absent in the nucleus. A relevant increase of cellular 
dimensions closely correlated to the concentration of nanoparticles can also be observed.  
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Figure 1. Optical images of human glioblastoma cells (T98G and U251) after 24 h of incubation 
with rhamnose-coated MNPs as a function of iron concentration in the culture medium (scale 
bars = 20 μm). 
 
In order to confirm the presence of nanoparticles inside the cells, Transmission Electron 
Microscopy (TEM) images were taken (Figure 2). These images show how nanoparticles and the 
plasma membrane interact: indeed, MNPs are observed both on the membrane surface (Figure 
2a) and, after internalization, in lysosomes (Figure 2b). The cell membrane invaginations and 
vacuole formation are indicative of endocytosis, whereas the membrane extrusions are connected 
to phagocytosis. The high number of these membrane modifications confirms the strong 
tendency of the cells to capture MNPs. These are localized under membrane ruffles and in 
internalized vesicles (Figure 2c). MNPs concentrated in cytoplasmic vesicles do not have any 
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precise compartmentalization. These vesicles migrated to the perinuclear region and fused with 
other vesicles forming larger phagosomes (Figure 2d). This phenomenon is particularly evident  
Figure 2. TEM images of T98G cells at C[Fe] = 25 μg/mL. MNPs can be localized in different 
 positions: attached on plasma membrane (a), internalized by pseudopodia, p, or incorporated 
into phagosomes, arrows (b). Note the high number of pseudopodia, p, indicating the strong 
tendency of the cell to capture MNPs (c). The vesicles in the perinucleal region (n = nucleus) are 
fused forming larger phagosomes (d). Similar considerations are valid for U251 cell line (see 
Supplementary Information).  
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at high concentrations of nanoparticles.  
To study quantitatively the uptake of MNPs and to disclose the mechanisms of MNP-cell 
interactions, a broad-band 1H-NMR investigation was performed23. We chose 20 MHz as 
working frequency, reaching a good compromise between sensitivity (i.e. signal intensity) and 
easiness of the method, being 20 MHz the typical frequency of commercial largely available 
bench-top NMR spectrometers. Using a step by step optimization, we were able to achieve a 
preparation protocol that allowed us to obtain in vitro samples suitable for NMR measurements. 
At the end of the process, the cells are well dispersed in a liquid matrix and the samples are 
homogeneous. Several different iron concentrations were used, covering the range 0.5 μg/mL - 
500 μg/mL. 1H-NMR transversal (T2) nuclear relaxation time was measured beginning with the 
first acquisition at 2 hours from sample preparation and concluding the protocol within a few 
hours, in order to avoid cell death and sample deterioration. In this way, even if all the 
measurements were performed at room temperature, we can consider the cells alive throughout 
the experiment’s short duration (see Supporting Information for details).  
The effect of different concentrations of MNPs in the measured in vitro samples has been 
studied by investigating the relaxation curve of the transverse nuclear magnetization, due to the 
great sensitivity of this mechanism to the local inhomogeneities with respect to the relaxation of 
the longitudinal component of the nuclear relaxation. In a water solution the transverse decay is 
described by a single exponential behaviour with a time constant T2. In the present case, a more 
complex behaviour was observed: two different contributions to the nuclear transverse relaxation 
curve were observed, a “T2 fast component” (T2,FAST) and a “T2 slow component” (T2,SLOW), 
clearly distinguished according to T2 length (see insets of Figure 3a and 3b). As can be noticed 
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by looking at Table 1, the absolute values of these two components differ by approximately one 
order of magnitude, both for T98G and U251. The values of the relaxation rates 1/T2,FAST and 
1/T2,SLOW as a function of MNPs iron concentration (C[Fe]) are shown in Figure  
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Figure 3. 1H-NMR data and volume evaluations as a function of iron concentration. Fast (,◆) 
and slow (,) transverse relaxation rates for T98G (a) and U251 (b) cells as a function of iron 
concentration (C[Fe]) are shown. The fits were performed using a logistic function (Eq. 1). The 
insets in (a) and (b) show two typical decay curves normalized to 1 in semi-logarithmic scale: the 
bi-exponential behaviour is clearly visible. Relative normalized weights of T2 fast and slow 
components as a function of C[Fe] for T98G (c) and U251 (d) are also shown (, and ◆, 
respectively). The error was quantified as 10% for both T2 and weights values (see 
Supplementary Information for details). The centre of the colored bands represents the intra-
cellular and the extra-cellular volumes calculated on the basis of the average diameter estimated 
with optical microscopy. The bandwidth corresponds to the experimental error. 
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Table 1 | Transverse relaxation times and dose-response fit results*. 
 
 
T2,FAST T2,SLOW 
T98G 
Values (ms) 0.1 ÷ 11.5 5.5 ÷ 51.0 
EC50 44 ± 17 1.7 ± 0.1 
p 1.02 ± 0.08 1.7 ± 0.1 
U251 
Values (ms) 1.7 ÷ 30.0 16.0 ÷ 300.0 
EC50 10 ± 5 117 ± 40 
p 1.0 ± 0.1 0.71 ± 0.07 
* The quality of the fit is confirmed by 2R values, always greater than 0.93. 
 
3a and 3b for T98G and U251 cell lines respectively. In Figure 3c and 3d we report the 
normalized relative weights of T2,FAST and T2,SLOW components. 
By a simultaneous analysis of microscope images, both optical and electronic, and NMR 
results, it was possible to identify the proton groups giving rise to different T2 components as 
belonging to different biological environments. To do this, we recall that in MRI in vivo images 
of brain a multi-exponential analysis of the T2 relaxation curves allowed the contribution of 
slowly relaxing “free protons” (coming from extra-cellular water) to be separated from that of 
fast relaxing “not-free protons” (pertaining to intra-cellular water)24,25. Following this distinction, 
the slow relaxing component (1/T2,SLOW) can be attributed to “free protons” of bulk water in 
direct contact only with MNPs on the cells membrane surface or at the beginning of the 
phagocytosis process. On the other hand, the fast relaxing component (1/T2,FAST) can be 
associated with the intra-cellular environment, i.e. to the “not-free protons” (that is with limited 
motion) of intra-cellular water and of MNP coating. Given that the T2 value is inversely 
proportional to the superparamagnetic particle concentration26, we can assume that T2,FAST and 
T2,SLOW are indirect measurements of the amount of MNPs in the intra-cellular and in the extra-
cellular environment, respectively. 
 11 
In order to quantify the degree of uptake as a function of C[Fe], our data were fitted by a logistic 
curve, a well-known model commonly used in physiological and pharmacological studies to 
investigate the dose-response behaviour of hormones, drugs and neurotransmitters27. In our case, 
it takes the following analytical form: 
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where 1/T2 is the “response” and C[Fe] is the “dose”. The parameter (1/T2)control represents the 
blank response and it was fixed equal to the experimental value measured for the control sample 
(i.e. with no MNPs incubation); (1/T2)max  is the saturation response value and it was chosen 
near the 1/T2 experimental value for C[Fe] = 500 µg/mL. The quantity p is the slope factor, 
which gives the maximum slope of the curve, while EC50 is the half maximal effective 
concentration. The values obtained from the fit procedure are shown in Table 1. Despite the wide 
range of concentrations (almost five orders of magnitude), the logistic fit performed on the NMR 
data worked well, as seen in Figure 3a and 3b. This is further evidence of the fact that rhamnose-
coated iron-oxide NPs are internalized by cells through an active mechanism, as explained 
below. Indeed, one has to observe that, since the logistic model is typical of agonist/receptor 
interactions28-30, its applicability to this case could be an indirect indication of receptor-mediated 
endocytosis or phagocytosis. In particular, the uptake mechanism of these two glioblastoma cell 
lines is similar to that of macrophages and the massive presence of long pseudopodia leads us to 
hypothesize a phagocytosis by carbohydrate-binding proteins, such as lectins, strongly involved 
in cancer communications31. 
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From a quantitative point of view, the NMR results confirm the great phagocytic activity 
already highlighted by optical and TEM images. Indeed, the internalization process does not stop 
until very high concentrations, as demonstrated for both the cell lines (T98G and U251) by 
1/T2,FAST maximum value, which is reached only for high iron concentrations (C[Fe] > 
100 µg/mL). Furthermore, by comparing EC50 values evaluated from T2,FAST curves, we gather 
that U251 cells show a more rapid internalization in respect to T98G (EC50T98G > EC50U251 for 
T2,FAST). As a consequence, 1/T2,SLOW of U251 cells increases more slowly than the one of T98G 
cells, confirming the fact that, in this cell line, at low and intermediate concentrations, few MNPs 
remain in the extra-cellular environment. 
Finally, by increasing the MNP concentration, the weight of the T2,FAST component increases, 
while the one of T2,SLOW diminishes (Figure 3c and 3d), indicating a rising amount of intra-
cellular water. This evidence of a turgor pressure enhancement, probably due to cellular 
swelling, is confirmed by a simple statistical analysis which shows an increase in average cell 
diameter (+28% for T98G and +14% for U251 at 50 µg/mL) as a function of concentration. The 
intra-cellular and extra-cellular volumes can be estimated using cell diameter data (see Summary 
Methods for details): the quantitative agreement between these estimations and the changes of 
the relative weight of fast and slow T2 components can be seen in Figure 3c and 3d. 
Gold nanoparticles (GNPs). The ability to obtain information on the uptake process using 
broadband 1H-NMR was then tested on in vitro samples incubated with non-magnetic 
nanostructures. Considering the great interest in metallic nanoparticles and their wide use in  
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Figure 4. 1H-NMR data and volume evaluations as a function of gold concentration. NMR 
weights of the two T2 components, fast and slow, are shown for (a) T98G ( and  
respectively) and (b) U251 (◆ and  respectively). The volume evaluations obtained with 
optical microscopy are shown as colored bands, grey for intra-cellular volume and red for the 
extra-cellular one. The bandwidth corresponds to the experimental error. 
 
biomedical application as e.g. sensors, we chose fully biocompatible gold nanoparticles (metallic 
core = 16.7 ± 1.6 nm) coated with sodium citrate32. 
Optical microscopy was performed on glioblastoma cells (both T98G and U251) after 24 hours 
of incubation with GNPs (images reported in Supplementary Information) and the average 
diameter was evaluated for different gold concentrations. As observed for MNPs, these 
experiments show an intra-cellular distribution at cytoplasmic level for both cell lines, without 
significant differences. In order to obtain in vitro samples suitable for NMR measurements, the 
same preparation procedure adopted for MNPs was used for GNPs. The range of concentrations 
explored covers almost three orders of magnitude, going from 1 µg/mL to 750 µg/mL (1000 
µg/mL for T98G). Two different transverse nuclear relaxation times, i.e. T2,FAST and T2,SLOW , 
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were measured. Using the previous arguments, they can be associated with the intra-cellular and 
with the extra-cellular environment respectively. The weights of the two T2 components, 
normalized with respect to the total signal intensity, are reported in Figure 4. The volume 
percentages of intra- and extra-cellular volumes calculated starting from the average diameter 
estimated with optical microscopy are also shown. As can be seen, the agreement between the 
data obtained with two different techniques (NMR and optical microscopy) is fully within the 
error, proving once more the capability of 1H-NMR to probe the sample at a microscopic level. 
In the case of GNPs, a quantitative estimation of the T2 evolution as a function of gold 
concentration C[Au] will require a future detailed investigation, due to the gold diamagnetism, 
whose influence on T2 is still not well understood.  The stimulated response of the system (by the 
presence of GNPs) is reflected by the behaviour of the relative weights of the two components. 
An increase in intra-cellular weight with increasing Au concentration can be observed for both 
cell lines, indicating cellular swelling (volume increase), possibly due to the cellular stress 
induced by GNP phagocytosis. In particular, T98G cell line weights of T2 components are 
characterized by a monotonic variation over the whole range of concentrations C[Au], while U251 
exhibit a more rapid increase at very low C[Au] (< 100 µg/mL) followed by a plateau. This 
observation confirms a faster internalization process for U251 cells with respect to T98G, as 
already proved in the MNPs case. 
Temozolomide (TMZ). Additional experiments on the same apparatus were performed on 
glioblastoma cells incubated with temozolomide (TMZ), a specific antitumor drug which has the 
ability to pass through the blood-brain barrier33,34. TMZ has a cytotoxic effect caused by the 
methylation of the O6 position of guanine, which causes a DNA double-strand break and 
initialization of an apoptosis pathway35.  In accordance with standard treatment protocols, the  
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Figure 5. 1H-NMR data and volume evaluations as a function of temozolomide concentration. 
NMR weights of the two T2 components, fast and slow, are shown for (a) T98G ( and  
respectively) and (b) U251 (◆ and  respectively). The volume evaluations obtained with 
optical microscopy are shown as colored bands, grey for intra-cellular volume and red for extra-
cellular one. The bandwidth corresponds to the experimental error. 
 
cells cultures (T98G and U251) were incubated with TMZ for two hours. After this short period 
the samples were measured by 1H-NMR within a few hours, in order to avoid extra toxicity 
effects due to the extended action of the drug. A wide range of concentrations was explored, 
starting from 5 µM to 400 µM: the dose indicated by common in vitro treatment plans is 20 µM. 
Also in this case, 1H-NMR is able to distinguish between the fast relaxing signal (T2,FAST) 
coming from intra-cellular protons and the slow relaxing signal (T2,SLOW) from extra-cellular 
protons. The weight of each component gives a quantitative estimation of the amount of protons 
in each biological environment (i.e. intra- and extra-cellular). They are reported in Figure 5 for 
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T98G and U251 cell lines, together with an estimation of the volumes obtained from the optical 
microscopy measurements of diameter.  
Instead of a monotonic behaviour of the weights as a function of concentration of MNPs and 
GNPs, some anomalous features can be observed when cells are treated with TMZ. In particular, 
for very low drug doses, i.e. C[TMZ] < 10 µM, an increase in intra-cellular weights for both T98G 
and U251 is observed, confirmed by optical microscopy data. This behaviour is an indication of 
autophagy, a stress reaction caused by TMZ that induces cellular turgor36, but still compatible 
with cell alive. By increasing the drug dose in the range 10 µM < C[TMZ] < 30 µM, a fast decrease 
of the intra-cellular weight for both cell lines can be noticed. This decreasing trend is only 
partially confirmed by the volume reduction detected by means of optical microscopy. Actually, 
an important gap among the percent weights and volumes opens up around the common 
treatment dose, i.e. 20 µM. This discrepancy can be explained by considering that during the 
incubation time, a fraction of cells dies by apoptosis and detach easily from the plate. These cells 
are then washed away during the sample preparation and do not contribute to the intra-cellular 
NMR signal. On the other hand, optical microscopy evaluates the cell diameter, but is not 
sensitive to the total number of cells. 
For very high doses (C[TMZ] > 50 µM), the NMR weights reach a sort of plateau, confirming 
that the killing action of the drug is complete. By considering the value of the gap between NMR 
percent weights and volumes estimated by microscopy, the fraction of dead cells can be 
quantified as 30% for T98G and 40-45% for U251. A decrease of the cells diameter as a function 
of concentration is still visible. This observation reveals that the surviving cells are close to 
apoptosis, the shrinkage being a common effect of this process40. 
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In summary, 1H-NMR revealed itself as a powerful tool to investigate the microscopic 
properties of in vitro cell cultures in presence of exogenous nanostructures, having the capability 
to probe both the intra- and extra-cellular 1H-based environment. We studied the response of two 
different glioblastoma cell lines exposed to three different exogenous agents, i.e. magnetic 
nanoparticles, gold nanoparticles and an antitumor drug, following the phenomena over a wide 
range of concentration (at least three orders of magnitude).  
By evaluating the transverse nuclear relaxation times, we demonstrated the existence of an 
uptake law for rhamnose coated iron-oxide MNPs in human glioblastoma tumor cells. 
Furthermore, cell swelling and cell death can be easily investigated as a function of 
concentration when external agents of different nature (magnetic nanoparticles, metallic 
nanoparticles, drugs) are incubated with cells. The presented experiment could be considered an 
innovative method and represent a new general strategy to improve the knowledge of the uptake 
process and of the intra- and/or extra- cellular localization of a variety of nanostructured 
compounds. 
Methods Summary. To investigate the cellular uptake of MNPs, we chose rhamnose-coated 
iron-oxide nanoparticles22 as an efficient bifunctional targeting system for theranostic 
applications, because of the high MRI contrast efficiency, the good magnetic hyperthermia effect 
and the marked tendency of the rhamnose coating to target skin tumours. These nanoparticles are 
also biocompatible and non-toxic. The magnetic core, made of magnetite (Fe3O4), has a spherical 
geometry with a diameter of 18.2 ± 1.1 nm (TEM characterization), while the hydrodynamic 
diameter for the whole nanoparticle is 23 nm. All these details are reported in Ref. 16. Citrate-
capped gold nanoparticles were prepared using a modified version of the standard Turkevich 
method32; the mean size of the spherical particles is 16.7 ± 1.6 nm, as estimated by TEM 
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imaging. As biological systems, we used two kinds of human glioblastoma immortalized cell 
lines, i.e. T98G and U251.  
The incubation of such cells with MNPs was performed in a plate and the experimental 
observations allowed us to exclude any sedimentation effects on the cellular uptake process37. 
Optical and TEM images were acquired using standard protocols and instruments: the details are 
given in the Supplementary Information. Using optical microscopy images, the average cell 
diameter (± 0.5 µm) was estimated for different MNPs, GNPs and TMZ concentrations. 
In order to obtain in vitro samples suitable for NMR measurements, an original sample 
preparation protocol was developed. After the incubation time with the external agent (24 h for 
MNPs and GNPs, 2 h for TMZ), several washings and centrifugations were performed and a 
cellular pellet without free (not absorbed) nanoparticles and other impurities (like dead cells) that 
could give rise to spurious NMR signals was obtained. Then, at the end of the preparation, 10 μL 
of clean culture medium was added.  
The evaluation of the intra-cellular volume in the NMR sample was calculated as follows, 
using average cell diameters data: (Single Cell Volume) × (Number of Cells), where the number 
of cells is 5 · 106 for T98G and 4 · 106 for U251, taking into account their different growth rates. 
The extra-cellular volume was quantified as 10 μL + 5 μL, considering the clean culture medium 
added at the end of the preparation and a reasonable experimental error. 
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